{"global_stoichiometry": "Hetero 2-mer - AB ", "ligstr": "", "uniprot_ac": "", "inchi": "", "reference": "Sci Rep. 2015 Apr 16;5:9649.", "author": "Crespi, G.A., Hermans, S.J., Parker, M.W., Miles, L.A.", "type": "Inhibitor complex", "ligand_id": "", "species": "", "method": "X-RAY DIFFRACTION", "keyword": "", "gene_names": "IGKC & IGHG1 & APP, A4, AD1 & IGKC & IGHG1 & APP, A4, AD1", "chain_id": "", "ligand_mw": "", "inchi_key": "", "secondary_structure": "DVVMTQSPLSLPVTLGQPASISCRSSQSLIYSDGNAYLHWFLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC#CCCCEEECSEEEEETTCCEEEEEECSSCCBCTTSCBCEEEEEECTTSCCEEEECSSSCBCTTCCSSEEEEEETTEEEEEESSCCGGGCEEEEEEECSSSSCEECCCEEEEEECCCBCCEEEEECCCHHHHHTTEEEEEEEEEEEBSSCCEEEEEETTEECCSSEEEEECCCCSSSCCEEEEEEEEEEHHHHHTCSEEEEEEECTTCSSCEEEEEETTCC&EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYSMSWVRQAPGKGLELVAQINSVGSSTYYPDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHHHH#CCEEEEESCSEECTTCCEEEEEEEESSCGGGSCEEEEEECTTCCCEEEEEECSSSCCEECCTTTTTTEEEEEETTTTEEEEEECSCCGGGCEEEEEECSSCBCCCEEEEECSSCCBCCEEEEECCCCCCCCCCEEEEEEEEEEEBSSCCEEEETTTTBCTTEEECCCEECTTSCEEEEEEEEEESHHHHHCCEEEEEEEGGGTEEEEEEECCCCCCCCCCCCC&VHHQKLVFFAEDVGSNK#CCCCCCCCSGGGTTCCC&DVVMTQSPLSLPVTLGQPASISCRSSQSLIYSDGNAYLHWFLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC#CCCEEEECSEEEEETTSCEEEEEEESSCCBCTTCCBCEEEEEECSSSCEEEEESSSSCBCTTCCTTEEEEEETTEEEEEESSCCTTSCEEEEEEECSSSSCEEBCCEEEEEECCCBCCEEEEECCCHHHHTTTEEEEEEEEEEEBSSCCEEEEEETTEECCSCEEEEECCCCSSSCCEEEEEEEEEEHHHHHHCCCEEEEEECSSSSSCEEEEECCCCC&EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYSMSWVRQAPGKGLELVAQINSVGSSTYYPDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHHHH#CCEEEEECCEEECTTCCEEEEEEEESSCGGGSCEEEEEECTTCCCEEEEEECSSSSCEECCTTTTTTEEEEEETTTTEEEEEECSCCGGGCEEEEEECSSCBCCCEEEEECSSCCBCCEEEEECCCCCCCCCCCEEEEEEEEEEBSSCCEEEEGGGTCCTTEEECCCEECTTSCEEEEEEEEECGGGTTTSCCEEEEEETTTTEEEEEECCCCCCCCCCCCCC&VHHQKLVFFAEDVGSNK#CCCCCCCCSGGGCCCCC", "amyloid_non_amyloid": "Non-amyloid", "length": "219 ,  223 ,  17 ,  219 ,  223 ,  17", "remarks": "Crystal Structure of mid-region amyloid beta capture by solanezumab", "protein_name": "Ig kappa chain C region", "peptide_protein_sequence": "chain-ID A: DVVMTQSPLSLPVTLGQPASISCRSSQSLIYSDGNAYLHWFLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC; chain-ID B: EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYSMSWVRQAPGKGLELVAQINSVGSSTYYPDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHHHH; chain-ID C: VHHQKLVFFAEDVGSNK; chain-ID D: DVVMTQSPLSLPVTLGQPASISCRSSQSLIYSDGNAYLHWFLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC; chain-ID E: EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYSMSWVRQAPGKGLELVAQINSVGSSTYYPDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHHHH; chain-ID F: VHHQKLVFFAEDVGSNK", "ligand_name": "", "ligand_smiles": "", "pdb_id": "4XXD", "ec_number": "", "pdb_classification": "IMMUNE SYSTEM", "mutation_s_field": "No", "ligand_formula": "", "r_value_free": "0.29", "alternative_name": "Ig kappa chain C region, Ig kappa chain C region AG, Ig kappa chain C region CUM, Ig kappa chain C region EU, Ig kappa chain C region OU, Ig kappa chain C region ROY, Ig kappa chain C region TI & Ig gamma-1 chain C region, Ig gamma-1 chain C region EU, Ig", "description": "Solanezumab (Eli Lilly) and crenezumab (Genentech) are the leading clinical antibodies targeting Amyloid-Beta (ABeta) to be tested in multiple Phase III clinical trials for the prevention of Alzheimer's disease in at-risk individuals. ABeta capture by these clinical antibodies is explained here with the first reported mid-region ABeta-anti-ABeta complex crystal structure. Solanezumab accommodates a large ABeta epitope (buried interface over residues 16 to 26) that forms extensive contacts and hydrogen bonds to the antibody, largely via main-chain ABeta atoms and a deeply buried Phe19-Phe20 dipeptide core. The conformation of ABeta captured is an intermediate between observed sheet and helical forms with intramolecular hydrogen bonds stabilising residues 20-26 in a helical conformation.", "resolution": "2.41", "pmid": "25880481", "entry": "S-0407"}